Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Medrad Collaborates With B Braun Melsungen

Medrad has entered into a co-marketing and trademark license agreement with Germany-based B Braun Melsungen to promote the Paccocath technology, a clinically tested technology used to treat blocked vessels without stenting.

The Paccocath technology has been shown, in multiple clinical trials, to keep the artery open wider (reduce late lumen loss) over time in patients with Peripheral Arterial Disease and Coronary Artery Disease (CAD). It will be used in both Medrad’s and B Braun’s drug-eluting balloons.

Under the agreement, B Braun is permitted to use the Paccocath trademark in connection with promotion and marketing of its drug eluting balloon products. B Braun has licensed the Paccocath technology for use on its ‘SeQuent Please’ Drug Eluting Balloon Catheter, for the treatment of narrowing of the coronary arteries. SeQuent Please has received the CE mark and is available in all those countries which accept the CE certificate, said the company.

The Paccocath technology is a drug matrix applied to the balloon of an angioplasty catheter. The matrix consists of paclitaxel, which has long been used in drug-eluting stents to treat cardiovascular disease, and a radiologic contrast agent, Ultravist 370.

Kraig McEwen, senior vice president of Medrad Interventional/Possis, said: “We feel it is important to distinguish the positive clinical results of the unique Paccocath technology in the marketplace. This agreement allows us to do that in cooperation with B Braun.”

Gerd Wacker, senior vice president of B Braun and Vascular Systems, said: “We are delighted to be able to develop and market the Paccocath technology, which provides both companies the opportunity to offer a greater variety of products designed to improve patient treatment and outcomes.”